Changing the world
UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.
Freeline secures over £88 million of funding
Freeline Therapeutics Ltd (“Freeline”), a clinical stage company focused on treatment of chronic systemic diseases with liver targeted adeno-associated virus (AAV) gene therapy, announces today that it has raised over £88 million of new capital in a Series B financing round. Syncona Ltd (“Syncona”) led the new investment committing £85 million, with The UCL Technology Fund, committing £3.4 million to the series B funding. This augments the previous £33.5 million Series A investment from founding investor Syncona.
Novel method of analysis of stroke data
Latest news and highlights
Bringing innovation to life